Most disputes between pharmaceutical companies and generic drugmakers end in settlements. Five years of class-action litigation over a Takeda Pharmaceutical gastrointestinal drug culminated this week ...

Hims & Hers Health (HIMS) on Thursday announced the launch of generic versions of Novo Nordisk’s (NVO) blockbuster GLP-1 therapy semaglutide through its telehealth platform in Canada. The ...

Telehealth provider Hims & Hers Health Inc. announced Thursday the availability of generic semaglutide through its platform, allowing eligible Canadians access to digital prescriptions for the popular ...

1:24 Health Canada approves generic semaglutide for adults with type 2 diabetes Two generic versions of Ozempic and Wegovy are set to start arriving in Canadian pharmacies this week, which means ...

The audio version of this article is generated by AI-based technology. Mispronunciations can occur. We are working with our partners to continually review and improve the results. Some Canadian ...

The Trump administration has expanded TrumpRx to include more than 600 generic medications — a significant scale-up from the platform’s original focus on branded drugs under most-favored-nation ...

The Trump administration is joining forces with Mark Cuban’s Cost Plus Drugs, Amazon Pharmacy, and GoodRx to add generic medications to the direct-to-consumer drug sales website, TrumpRx, in an ...

Indian pharmaceutical companies, long celebrated as the “Pharmacy of the World,” are undergoing a structural transformation. While traditional simple generics (basic oral solids) continue to deliver ...

Novo Nordisk has flagged growing generic competition in markets including India as a potential drag on its international business in 2026, highlighting rising pressure on branded obesity and diabetes ...

India got it earlier this year, and Canada approved it last month. But when is the United States going to get a generic version of Ozempic? Subscribe to read this story ad-free Get unlimited access to ...

As a significant wave of high-value medicines nears the end of patent protection, attention is quickly turning to how companies can bring more affordable generic and biosimilar alternatives to ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. The day has ...